Work

Reimagining medical affairs through strategic leadership in patient partnering healthcare

Year: 2025

Type: article

Abstract: Medical affairs (MA) has transformed to become a strategic pillar in the pharmaceutical ecosystem. This article highlights the expanding role of MA across the drug lifecycle, from patient access to clinical adoption and evidence generation. By exploring the shift from 'patient centricity' to 'patient as partner', we emphasize how MA can bridge innovation with real healthcare needs. Case studies illustrate how MA actions impact patient outcomes beyond the treatment provided. As expectations from stakeholders rise, MA must lead with patient partnering as a strategic priority. Patient focus is no longer optional; it is a core driver of value for patients and industry.

Source: Drug Discovery Today

DOI: 10.1016/j.drudis.2025.104558

Authors: Sébastien Reig, Christel Becker

Institutions: Novartis (France), Inserm, Université Paris Cité, Health and Functional Exposomics

Language: English

Topic: Pharmaceutical industry and healthcare

Subfield: Pharmacology

Field: Pharmacology, Toxicology and Pharmaceutics

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,720